Abstract | INTRODUCTION: AIMS: The study included three age-, weight-, and lipid-matched groups of older men with atherogenic dyslipidemia and late-onset hypogonadism, treated with oral testosterone undecanoate (120 mg daily, n = 15), micronized fenofibrate (200 mg daily, n = 15), or testosterone plus fenofibrate (n = 18). Plasma lipids, glucose homeostasis markers, as well as plasma levels of androgens, uric acid, high-sensitivity C-reactive protein ( hsCRP), homocysteine, and fibrinogen were assessed before and after 16 weeks of therapy. RESULTS: Apart from an increase in plasma testosterone and a reduction in HDL cholesterol, testosterone undecanoate tended to decrease hsCRP and to improve insulin sensitivity. Fenofibrate administered alone increased HDL cholesterol, reduced triglycerides, decreased insulin resistance, reduced circulating levels of uric acid, hsCRP, and fibrinogen, as well as increased plasma levels of homocysteine. The strongest effect on testosterone, HOMA1-IR, uric acid, hsCRP, and fibrinogen was observed if fenofibrate was administered together with testosterone. Testosterone- fenofibrate combination therapy was also devoid of unfavorable effect on HDL cholesterol and homocysteine. CONCLUSIONS:
|
Authors | Robert Krysiak, Wojciech Gilowski, Bogusław Okopien |
Journal | Cardiovascular therapeutics
(Cardiovasc Ther)
Vol. 33
Issue 5
Pg. 270-4
(Oct 2015)
ISSN: 1755-5922 [Electronic] England |
PMID | 26031507
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2015 John Wiley & Sons Ltd. |
Chemical References |
- Biomarkers
- Blood Glucose
- Cholesterol, HDL
- Hypolipidemic Agents
- Lipids
- Testosterone
- testosterone undecanoate
- Fenofibrate
|
Topics |
- Aged
- Biomarkers
- Blood Glucose
- Cardiovascular Diseases
(metabolism)
- Cholesterol, HDL
(metabolism)
- Dyslipidemias
(drug therapy)
- Fenofibrate
(pharmacology, therapeutic use)
- Humans
- Hypogonadism
(drug therapy)
- Hypolipidemic Agents
(pharmacology, therapeutic use)
- Lipids
(blood)
- Male
- Middle Aged
- Prospective Studies
- Risk Factors
- Testosterone
(analogs & derivatives, pharmacology, therapeutic use)
|